Key Points
- CEO Dinesh Ph Patel sold 65,761 shares at an average price of $149.11, generating approximately $9.81 million. The sale reduced his direct ownership by 11.16% and was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Protagonist Therapeutics exceeded quarterly expectations, reporting $2.29 in EPS versus the $2.27 consensus estimate and $213.47 million in revenue. Revenue rose 3,746.8% year over year, while net margin was 29.4%.
- Analyst sentiment remains broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $137.86; institutional investors own approximately 98.63% of outstanding shares.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CEO Dinesh Ph Patel sold 34,239 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $148.52, for a total transaction of $5,085,176.28. Following the completion of the sale, the chief executive officer directly owned 523,478 shares in the company, valued at $77,746,952.56. This trade represents a 6.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Protagonist Therapeutics Stock Performance
Shares of PTGX stock opened at $152.01 on Thursday. The firm has a fifty day moving average of $127.64 and a 200-day moving average of $106.78. The stock has a market cap of $9.84 billion, a price-to-earnings ratio of 147.58 and a beta of 1.78. Protagonist Therapeutics, Inc. has a 52-week low of $54.18 and a 52-week high of $152.70.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.02. The business had revenue of $213.47 million for the quarter, compared to analyst estimates of $212.03 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. Protagonist Therapeutics's revenue for the quarter was up 3746.8% on a year-over-year basis. On average, sell-side analysts predict that Protagonist Therapeutics, Inc. will post 4.02 earnings per share for the current year.
Key Headlines Impacting Protagonist Therapeutics
Here are the key news stories impacting Protagonist Therapeutics this week:
- Positive Sentiment: An analyst article maintained a “Strong Buy” view, citing FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, attractive partnership economics and additional pipeline opportunities. Investors are also watching the FDA’s expected August 2026 Priority Review decision for rusfertide, which could lead to significant milestones and royalty payments from Takeda. The company plans to begin a Phase 2b study of oral IL-17 antagonist PN-881 in the first quarter of 2027. Protagonist Therapeutics: Strong Buy—ICOTYDE FDA Approval and PN-881 Advancement
- Positive Sentiment: A psoriasis-focused stock roundup included PTGX among companies offering exposure to approved therapies, late-stage candidates and earlier-stage psoriasis programs. This reinforces investor interest in Protagonist’s inflammatory-disease pipeline, although the article does not provide a new company-specific catalyst. 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
- Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures appear anomalous, they provide little meaningful indication of near-term short-covering or bearish pressure.
- Negative Sentiment: CEO Dinesh V. Patel sold a combined 100,000 shares for approximately $14.9 million in transactions dated August 10 and 11. The sales reduced his reported ownership, which can pressure sentiment; however, both transactions were executed under a pre-arranged Rule 10b5-1 trading plan, making them less indicative of a fresh change in management’s outlook. SEC insider transaction filing
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on PTGX shares. Truist Financial upped their price objective on Protagonist Therapeutics from $145.00 to $170.00 and gave the company a "buy" rating in a research note on Monday. Wall Street Zen lowered Protagonist Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Johnson Rice set a $165.00 price target on Protagonist Therapeutics in a research note on Friday, July 17th. Zacks Research cut Protagonist Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 7th. Finally, TD Cowen reiterated a "buy" rating on shares of Protagonist Therapeutics in a research note on Wednesday, July 1st. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $137.86.
Read Our Latest Stock Analysis on PTGX
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of PTGX. BlackRock Inc. acquired a new position in shares of Protagonist Therapeutics in the 2nd quarter worth approximately $1,263,535,000. Vanguard Group Inc. increased its holdings in Protagonist Therapeutics by 27.2% during the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company's stock valued at $472,832,000 after purchasing an additional 1,156,461 shares in the last quarter. State Street Corp increased its holdings in Protagonist Therapeutics by 18.5% during the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company's stock valued at $177,281,000 after purchasing an additional 500,924 shares in the last quarter. Wellington Management Group LLP raised its position in Protagonist Therapeutics by 66.2% in the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company's stock valued at $276,992,000 after purchasing an additional 1,262,977 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in Protagonist Therapeutics by 9.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,891,527 shares of the company's stock valued at $304,866,000 after purchasing an additional 241,546 shares during the last quarter. Institutional investors own 98.63% of the company's stock.
Protagonist Therapeutics Company Profile
(
Get Free Report)
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
